Bente Mikkelsen: “Success is Something We Build Together”
From the bedside to global reform, and why equity must be engineered, not hoped for “I think I chose medicine because it gave all the opportunities to address people, both at a national level, but also internationally. And it’s a…
Karen Knudsen: The Scientist Who Refused to Move Slowly
“I’m a scientist first and foremost. I don’t remember a time not thinking about being a scientist.” What Karen Knudsen, the CEO of Parker Institute for Cancer Immunotherapy, remembers clearly…
Hesham Elghazaly: Pharaoh of Oncology
When he enters the bazaar, people stand up… They stop. They smile. They love him. This kind of love has nothing to do with titles, resources, or power. It is…
NEWS
The Day Immunotherapy Went Off-Patent
In oncology, some milestones arrive with applause. Others arrive quietly. This year, one of the most important cancer drugs of the modern era begins to lose its monopoly. Nivolumab, one of the first PD-1 inhibitors to reach patients, is set…
CONTENTS
ARTICLES
The Day Immunotherapy Went Off-Patent
In oncology, some milestones arrive with applause. Others arrive quietly. This year, one of the most important cancer drugs of the modern era begins to lose its monopoly. Nivolumab, one of the first PD-1 inhibitors to reach patients, is set…
